Trial Profile

Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabiralizumab (Primary) ; Carboplatin (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 Mar 2023 Planned End Date changed from 17 Jun 2027 to 31 May 2026.
22 Mar 2023 Status changed from recruiting to active, no longer recruiting.
10 Dec 2022 Interim results (n=12) presented at the 45th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com